As Merger With Wyeth Hangs In The Balance Of Beijing's Hands, Pfizer CEO Tours China To Launch Scholarly Partnerships

BEIJING - With the fate of a $68-billion merger with Wyeth now being reviewed by the Chinese leadership, Pfizer Chief Executive Officer Jeff Kindler is on a five-day, whirlwind tour of the country, in part to launch a new wave of partnerships with scientists and scholars